Uploaded April 2025 | Updated September 2026, 4 hours ago
What if we could control powerful CAR-T cell therapies like flipping a switch? At the Calibr-Skaggs Institute of Scripps Research, we're pioneering a next-generation "switchable" CAR-T (sCAR-T) platform—designed to tackle cancer and autoimmune diseases with greater precision, safety and durability.
Traditional CAR-T has been highly successful, but multiple barriers remain: off-target toxicity, T-cell ‘exhaustion’ (weakening of CAR-T cell response over time), and manufacturing challenges restrict the widespread use and application of traditional CAR-T to solid tumors. Our platform features a universal design with antibody-based “switches” that are selective for multiple disease-related targets—increasing specificity while reducing potential off-target effects.
Preliminary results from our phase 1 trial in B-cell malignancies are promising, and we are now gearing up to expand into solid tumors and autoimmune conditions. Watch to see how this innovative approach could transform the future of immunotherapy.
For more information on our platform and approach, please visit: https://calibr.scripps.edu/our-pipeline/scar-t/
What if we could control powerful CAR-T cell therapies like flipping a switch? At the Calibr-Skaggs Institute of Scripps Research, we're pioneering a next-generation "switchable" CAR-T (sCAR-T) platform—designed to tackle cancer and autoimmune diseases with greater precision, safety and durability.
Traditional CAR-T has been highly successful, but multiple barriers remain: off-target toxicity, T-cell ‘exhaustion’ (weakening of CAR-T cell response over time), and manufacturing challenges restrict the widespread use and application of traditional CAR-T to solid tumors. Our platform features a universal design with antibody-based “switches” that are selective for multiple disease-related targets—increasing specificity while reducing potential off-target effects.
Preliminary results from our phase 1 trial in B-cell malignancies are promising, and we are now gearing up to expand into solid tumors and autoimmune conditions. Watch to see how this innovative approach could transform the future of immunotherapy.
For more information on our platform and approach, please visit: https://calibr.scripps.edu/our-pipeline/scar-t/
